JP2024525792A - 治療に使用するための６Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］ピリジン誘導体 - Google Patents

治療に使用するための６Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］ピリジン誘導体 Download PDF

Info

Publication number
JP2024525792A
JP2024525792A JP2024502014A JP2024502014A JP2024525792A JP 2024525792 A JP2024525792 A JP 2024525792A JP 2024502014 A JP2024502014 A JP 2024502014A JP 2024502014 A JP2024502014 A JP 2024502014A JP 2024525792 A JP2024525792 A JP 2024525792A
Authority
JP
Japan
Prior art keywords
formula
compound
cancer
pharma
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024502014A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525792A5 (enExample
Inventor
アリーヌ・ムーラン
ジャン－フランソワ・ペイロネル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2024525792A publication Critical patent/JP2024525792A/ja
Publication of JP2024525792A5 publication Critical patent/JP2024525792A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024502014A 2021-07-16 2022-07-12 治療に使用するための６Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］ピリジン誘導体 Pending JP2024525792A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306000.7 2021-07-16
EP21306000 2021-07-16
PCT/EP2022/069471 WO2023285465A1 (en) 2021-07-16 2022-07-12 6h-imidazo[1,2-a]pyrrolo[2,3-e]pyridine derivatives for use in therapy

Publications (2)

Publication Number Publication Date
JP2024525792A true JP2024525792A (ja) 2024-07-12
JP2024525792A5 JP2024525792A5 (enExample) 2025-07-22

Family

ID=77126713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502014A Pending JP2024525792A (ja) 2021-07-16 2022-07-12 治療に使用するための６Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］ピリジン誘導体

Country Status (7)

Country Link
US (1) US20240294529A1 (enExample)
EP (1) EP4370516A1 (enExample)
JP (1) JP2024525792A (enExample)
CN (1) CN118234727A (enExample)
AR (1) AR126473A1 (enExample)
TW (1) TW202320753A (enExample)
WO (1) WO2023285465A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4370518A1 (en) * 2021-07-16 2024-05-22 Sanofi Imidazo[1,2-b][1,2,4]triazol derivatives for use in therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504309A (ja) * 2006-09-22 2010-02-12 サノフイ−アベンテイス ２−アリール−６−フェニルイミダゾ［１，２−α］ピリジン誘導体、これらの調製およびこれらの治療的使用
JP2011515382A (ja) * 2008-03-21 2011-05-19 サノフイ−アベンテイス 多置換２−アリール−６−フェニル−イミダゾ［１，２−ａ］ピリジン誘導体、ならびにこれらの調製および治療的使用
JP2011515383A (ja) * 2008-03-21 2011-05-19 サノフイ−アベンテイス ２−ヘテロアリール−６−フェニルイミダゾ［１，２−ａ］ピリジンの多置換誘導体、ならびにこの調製および治療への使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2928924B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
FR2950344B1 (fr) * 2009-09-18 2011-11-25 Sanofi Aventis Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique.
CA3138439C (en) * 2017-11-15 2023-05-23 Korea Research Institute Of Bioscience And Biotechnology Composition for preventing or treating neurodegenerative diseases, containing diterpene-based compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504309A (ja) * 2006-09-22 2010-02-12 サノフイ−アベンテイス ２−アリール−６−フェニルイミダゾ［１，２−α］ピリジン誘導体、これらの調製およびこれらの治療的使用
JP2011515382A (ja) * 2008-03-21 2011-05-19 サノフイ−アベンテイス 多置換２−アリール−６−フェニル−イミダゾ［１，２−ａ］ピリジン誘導体、ならびにこれらの調製および治療的使用
JP2011515383A (ja) * 2008-03-21 2011-05-19 サノフイ−アベンテイス ２−ヘテロアリール−６−フェニルイミダゾ［１，２−ａ］ピリジンの多置換誘導体、ならびにこの調製および治療への使用

Also Published As

Publication number Publication date
CN118234727A (zh) 2024-06-21
WO2023285465A1 (en) 2023-01-19
TW202320753A (zh) 2023-06-01
AR126473A1 (es) 2023-10-11
US20240294529A1 (en) 2024-09-05
EP4370516A1 (en) 2024-05-22

Similar Documents

Publication Publication Date Title
AU2018222073B2 (en) O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof
WO2021121371A1 (zh) Kras g12c抑制剂及其在医药上的应用
KR20210135561A (ko) 피라진 유도체 및 shp2 억제에서의 그의 적용
WO2022121813A1 (zh) Sos1抑制剂、包含其的药物组合物及其用途
CN118221698A (zh) Kras g12d抑制剂
CN118221685A (zh) 作为kras g12d抑制剂的吲哚类化合物
US20120165366A1 (en) Compounds and uses thereof
WO2001083481A1 (en) Imidazopyridine derivatives
WO2023280182A1 (zh) 作为kat6抑制剂的化合物
HUE029275T2 (en) Phthalazinone ketone derivative, method of preparation and therapeutic use
WO2021017880A1 (zh) 一类靶向stat3双功能磷酸化位点的三芳香环类化合物及其应用
WO2023138541A1 (zh) 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
WO2023274246A1 (zh) 酰胺类化合物及其用途
CN117088878A (zh) 一种高活性Wnt通路抑制剂化合物
TW201002725A (en) Thiazolyl-and oxazolyl-isoquinolinones and methods for using them
CN114456178B (zh) 四氢嘧啶[1,2-b]吲唑-4-胺类衍生物作为AhR抑制剂的用途及制备方法
EP3650448A1 (en) Indole-formamide derivative, preparation method therefor and use thereof in medicine
EP3413892B1 (en) Tetrahydroisoquinoline derivatives
CN112321568B (zh) 4-甲基吡咯取代的吲哚酮衍生物、其制备方法及其医药用途
CN115160309B (zh) Krasg12c突变蛋白杂环类抑制剂的制备及其应用
JP6526064B2 (ja) ピリドピリミジンジオン誘導体
TW200932217A (en) Substituted hydantoins
TW202320753A (zh) 用於治療的６ｈ－咪唑並［１，２－ａ］吡咯並［２，３－ｅ］吡啶衍生物
JP2024525791A (ja) 治療に使用するためのイミダゾ［１，２－ｂ］［１，２，４］トリアゾール誘導体
EP4240738B1 (en) Pyrazole derivatives as ret kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428